Scribe Therapeutics has been awarded more than $25 million by the California Institute for Regenerative Medicine to advance two preclinical CRISPR-based gene editing programs, STX-1200 and STX-1400, toward clinical trials.
STX-1200 targets LPA to lower lipoprotein(a) in patients with genetically elevated Lp(a), and STX-1400 targets apoc3 to durably reduce triglyceride-rich lipoproteins and address acute pancreatitis in severe hypertriglyceridemia and chylomicronemia syndromes.
The awards were made through CIRM’s Preclinical Development Program to support California-based projects moving discoveries toward human studies.
Both programs leverage Scribe’s X-Editor XE gene editing platform, engineered for enhanced activity, specificity, and deliverability, and are led by principal investigator Brett Staahl, Ph.D.
Scribe positions these programs alongside its clinical-stage lead asset STX-1150 as part of a strategy to develop single-dose, durable genetic medicines targeting key lipid drivers of atherosclerotic cardiovascular disease.
The company said the funding advances preclinical work intended to enable clinical entry and reflects CIRM’s objective to accelerate therapies for patients with unmet medical needs.
